Targeted anti-vascular therapies for ovarian cancer: current evidence.
Targeted anti-vascular therapies for ovarian cancer: current evidence.
复制标题
DOI：
10.1038/bjc.2012.541
复制
发表时间：
2013-02-05
影响因子：
8.8
通讯作者：
Kaye, S.
中科院分区：
文献类型：
--
作者：
Hall, M.;Gourley, C.;McNeish, I.;Ledermann, J.;Gore, M.;Jayson, G.;Perren, T.;Rustin, G.;Kaye, S.
关键词：
卵巢癌在大约75%的女性中处于晚期，尽管化疗等治疗方法有所改善，但1996年至1999年在英格兰和威尔士诊断的女性中，5年生存率仅为36%。超过80%的晚期卵巢癌患者会复发，尽管有很好的机会从进一步的化疗中缓解，但他们通常会死于疾病。采用序贯治疗策略以最大限度地提高生命质量和寿命，但患者最终对细胞毒性药物产生耐药性。对表征癌细胞的分子生物学的理解的扩展导致了靶向重要途径的新药物的快速开发，但卵巢癌生物学的异质性意味着没有主要缺陷。这篇综述试图讨论迄今为止在解决更普遍的目标适用于卵巢癌血管生成的进展。
Ovarian cancer presents at advanced stage in around 75% of women, and despite improvements in treatments such as chemotherapy, the 5-year survival from the disease in women diagnosed between 1996 and 1999 in England and Wales was only 36%. Over 80% of patients with advanced ovarian cancer will relapse and despite a good chance of remission from further chemotherapy, they will usually die from their disease. Sequential treatment strategies are employed to maximise quality and length of life but patients eventually become resistant to cytotoxic agents. The expansion in understanding of the molecular biology that characterises cancer cells has led to the rapid development of new agents to target important pathways but the heterogeneity of ovarian cancer biology means that there is no predominant defect. This review attempts to discuss progress to date in tackling a more general target applicable to ovary cancer—angiogenesis.
登录
查看更多内容
影响因子：
5.7
作者：
Hashimoto K;Man S;Xu P;Cruz-Munoz W;Tang T;Kumar R;Kerbel RS
通讯作者：
Kerbel RS
影响因子：
45.3
作者：
Giantonio, Bruce J.;Catalano, Paul J.;Benson, Al B., III
通讯作者：
Benson, Al B., III
影响因子：
7.8
作者：
BORNSTEIN, P
通讯作者：
BORNSTEIN, P
影响因子：
50.5
作者：
Biagi, J. J.;Oza, A. M.;Eisenhauer, E. A.
通讯作者：
Eisenhauer, E. A.
影响因子：
158.5
作者：
Burger, Robert A.;Brady, Mark F.;Liang, Sharon X.
通讯作者：
Liang, Sharon X.